AU3704101A
(en)
*
|
2000-02-17 |
2001-08-27 |
Amgen Inc |
Kinase inhibitors
|
ES2324981T3
(es)
*
|
2000-12-21 |
2009-08-21 |
Smithkline Beecham Corporation |
Pirimidinaminas como moduladores de la angiogenesis.
|
US7153871B2
(en)
|
2001-01-22 |
2006-12-26 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
|
US7205320B2
(en)
|
2001-01-22 |
2007-04-17 |
Memory Pharmaceuticals Corp. |
Phosphodiesterase 4 inhibitors
|
CA2451128A1
(en)
|
2001-06-26 |
2003-01-09 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of tnf-alpha expression
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
DK1438053T3
(da)
*
|
2001-10-17 |
2008-12-08 |
Boehringer Ingelheim Pharma |
Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
|
HUP0402245A3
(en)
*
|
2001-11-01 |
2010-03-29 |
Janssen Pharmaceutica Nv |
Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them
|
TWI329105B
(en)
*
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
US7338959B2
(en)
|
2002-03-01 |
2008-03-04 |
Smithkline Beecham Corporation |
Diamino-pyrimidines and their use as angiogenesis inhibitors
|
EP1515955A4
(de)
*
|
2002-06-17 |
2006-05-03 |
Smithkline Beecham Corp |
Chemisches verfahren
|
AU2003256616B2
(en)
|
2002-07-19 |
2009-08-27 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
|
CA2492911A1
(en)
*
|
2002-07-19 |
2004-01-29 |
Memory Pharmaceuticals Corporation |
6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
|
EP1534286B1
(de)
*
|
2002-07-29 |
2009-12-09 |
Rigel Pharmaceuticals, Inc. |
VERFAHREN ZUR BEHANDLUNG ODER PRûVENTION VON AUTOIMMUNKRANKHEITEN MIT 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN
|
WO2004032882A2
(en)
*
|
2002-10-10 |
2004-04-22 |
Smithkline Beecham Corporation |
Chemical compounds
|
EP1569908B1
(de)
|
2002-11-19 |
2010-09-15 |
Memory Pharmaceuticals Corporation |
Pyridin-n-oxidverbindungen alsphosphodiesterase-4-inhibitoren
|
UA80767C2
(en)
*
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
DE60331479D1
(de)
|
2002-12-20 |
2010-04-08 |
Pfizer Prod Inc |
Pyrimidin-derivate zur behandlung von anormalem zellwachstum
|
US7109337B2
(en)
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
US20040167132A1
(en)
*
|
2003-01-16 |
2004-08-26 |
Geetha Shankar |
Methods of treating conditions associted with an Edg-2 receptor
|
WO2004074244A2
(en)
|
2003-02-20 |
2004-09-02 |
Smithkline Beecham Corporation |
Pyrimidine compounds
|
KR101254371B1
(ko)
|
2003-07-18 |
2013-05-02 |
암젠 프레몬트 인코포레이티드 |
간세포 성장인자에 결합하는 분리된 항체
|
CN1849318B
(zh)
|
2003-07-30 |
2011-10-12 |
里格尔药品股份有限公司 |
用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
|
JP4741491B2
(ja)
|
2003-08-07 |
2011-08-03 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
抗増殖剤としての2,4−ピリミジンジアミン化合物および使用
|
WO2005046594A2
(en)
*
|
2003-11-06 |
2005-05-26 |
Celgene Corporation |
Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
|
JP2007532658A
(ja)
*
|
2004-04-16 |
2007-11-15 |
スミスクライン ビーチャム コーポレーション |
がんの治療方法
|
JP2007537235A
(ja)
|
2004-05-14 |
2007-12-20 |
ファイザー・プロダクツ・インク |
異常細胞増殖の治療用ピリミジン誘導体
|
WO2005111022A1
(en)
|
2004-05-14 |
2005-11-24 |
Pfizer Products Inc. |
Pyrimidines derivatives for the treatment of abnormal cell growth
|
JP2007537238A
(ja)
|
2004-05-14 |
2007-12-20 |
ファイザー・プロダクツ・インク |
異常細胞増殖の治療のためのピリミジン誘導体
|
WO2005118544A2
(en)
|
2004-05-18 |
2005-12-15 |
Rigel Pharmaceuticals, Inc. |
Cycloalkyl substituted pyrimidinediamine compounds and their uses
|
WO2006020564A1
(en)
*
|
2004-08-09 |
2006-02-23 |
Smithkline Beecham Corporation |
Pyrimidin derivatives for the treatment of multiple myeloma
|
KR20070084067A
(ko)
*
|
2004-10-13 |
2007-08-24 |
와이어쓰 |
N-벤젠설포닐 치환 아닐리노-피리미딘 동족체
|
GB2420559B
(en)
|
2004-11-15 |
2008-08-06 |
Rigel Pharmaceuticals Inc |
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
|
CN100516049C
(zh)
|
2004-11-16 |
2009-07-22 |
永信药品工业股份有限公司 |
抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成
|
CA2584295C
(en)
|
2004-11-24 |
2014-08-26 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
US7652009B2
(en)
|
2004-11-30 |
2010-01-26 |
Amgem Inc. |
Substituted heterocycles and methods of use
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
US8227455B2
(en)
|
2005-04-18 |
2012-07-24 |
Rigel Pharmaceuticals, Inc. |
Methods of treating cell proliferative disorders
|
WO2006129100A1
(en)
*
|
2005-06-03 |
2006-12-07 |
Glaxo Group Limited |
Novel compounds
|
US7491732B2
(en)
*
|
2005-06-08 |
2009-02-17 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
US20070203161A1
(en)
*
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US8986650B2
(en)
|
2005-10-07 |
2015-03-24 |
Guerbet |
Complex folate-NOTA-Ga68
|
US8926945B2
(en)
|
2005-10-07 |
2015-01-06 |
Guerbet |
Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
|
DE602006020611D1
(de)
|
2005-11-29 |
2011-04-21 |
Glaxosmithkline Llc |
Krebsbehandlungsverfahren
|
PT1968594E
(pt)
|
2005-11-29 |
2010-11-18 |
Glaxosmithkline Llc |
Tratamento de distúrbios neovasculares oculares tais como degeneração macular, estrias angióides, uveite e edema macular
|
US20080108664A1
(en)
|
2005-12-23 |
2008-05-08 |
Liu Belle B |
Solid-state form of AMG 706 and pharmaceutical compositions thereof
|
TW200736232A
(en)
*
|
2006-01-26 |
2007-10-01 |
Astrazeneca Ab |
Pyrimidine derivatives
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
WO2007092178A1
(en)
|
2006-02-10 |
2007-08-16 |
Amgen Inc. |
Hydrate forms of amg706
|
CA2642229C
(en)
|
2006-02-24 |
2015-05-12 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2007143483A2
(en)
*
|
2006-06-01 |
2007-12-13 |
Smithkline Beecham Corporation |
Combination of pazopanib and lapatinib for treating cancer
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
ATE497496T1
(de)
|
2006-10-19 |
2011-02-15 |
Rigel Pharmaceuticals Inc |
2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
|
CA2672438A1
(en)
|
2006-12-20 |
2008-07-03 |
Amgen Inc. |
Substituted heterocycles and methods of use
|
WO2008086014A2
(en)
|
2007-01-09 |
2008-07-17 |
Amgen Inc. |
Bis-aryl amide derivatives useful for the treatment of cancer
|
FR2911604B1
(fr)
|
2007-01-19 |
2009-04-17 |
Sanofi Aventis Sa |
Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
|
AU2008219166B2
(en)
|
2007-02-16 |
2013-05-16 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
|
NZ580671A
(en)
*
|
2007-04-16 |
2012-03-30 |
Hutchison Medipharma Entpr Ltd |
Pyrimidine derivatives
|
PT2188313T
(pt)
|
2007-08-21 |
2017-12-12 |
Amgen Inc |
Proteínas de ligação ao antigénio c-fms humano
|
EP2058307A1
(de)
|
2007-11-12 |
2009-05-13 |
Cellzome Ag |
Verfahren zur Identifizierung von mit JAK-Kinase wechselwirkenden Molekülen und zur JAK-Kinase-Reinigung
|
SG2014015085A
(en)
|
2008-04-16 |
2014-06-27 |
Portola Pharm Inc |
2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
ES2546502T3
(es)
|
2008-04-16 |
2015-09-24 |
Portola Pharmaceuticals, Inc. |
2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
|
AU2009238590A1
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
ES2645689T3
(es)
|
2008-05-21 |
2017-12-07 |
Ariad Pharmaceuticals, Inc. |
Derivados de fósforo como inhibidores de quinasas
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
WO2010003084A2
(en)
*
|
2008-07-02 |
2010-01-07 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
US20110301113A1
(en)
*
|
2008-09-26 |
2011-12-08 |
Concert Pharmaceuticals Inc. |
Pyridineamine derivatives
|
FR2942227B1
(fr)
|
2009-02-13 |
2011-04-15 |
Guerbet Sa |
Utilisation de tampons pour la complexation de radionucleides
|
US20120232102A1
(en)
|
2009-09-30 |
2012-09-13 |
Chun-Fang Xu |
Methods Of Administration And Treatment
|
US20120197019A1
(en)
*
|
2009-10-23 |
2012-08-02 |
Dharmesh Surendra Bhanushali |
Compositions and processes
|
WO2011058179A1
(en)
|
2009-11-16 |
2011-05-19 |
Ratiopharm Gmbh |
5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
|
WO2011069053A1
(en)
|
2009-12-04 |
2011-06-09 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
|
TW201201808A
(en)
*
|
2010-01-06 |
2012-01-16 |
Glaxo Wellcome Mfg Pte Ltd |
Treatment method
|
CA2794153C
(en)
|
2010-03-25 |
2018-01-02 |
Glaxosmithkline Llc |
Substituted indoline derivatives as perk inhibitors
|
BR112012029647A2
(pt)
|
2010-05-21 |
2016-08-02 |
Chemilia Ab |
novos derivados de pirimidinas
|
EP2575460A4
(de)
*
|
2010-05-26 |
2013-10-16 |
Glaxosmithkline Llc |
Kombination
|
DK2576541T3
(en)
|
2010-06-04 |
2016-05-30 |
Hoffmann La Roche |
Aminopyrimidine AS LRRK2 MODULATORS
|
WO2011161217A2
(en)
|
2010-06-23 |
2011-12-29 |
Palacký University in Olomouc |
Targeting of vegfr2
|
US20130165456A1
(en)
|
2010-08-26 |
2013-06-27 |
Tona M. Gilmer |
Combination
|
WO2012036919A2
(en)
|
2010-09-14 |
2012-03-22 |
Glaxosmithkline Llc |
Combination of braf and vegf inhibitors
|
JP2013539795A
(ja)
*
|
2010-10-14 |
2013-10-28 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Egfr発動性がんの細胞増殖の阻害方法
|
TW201300360A
(zh)
|
2010-11-01 |
2013-01-01 |
Portola Pharm Inc |
做為jak激酶調節劑之菸鹼醯胺
|
TW201238938A
(en)
|
2010-11-01 |
2012-10-01 |
Portola Pharm Inc |
Benzamides and nicotinamides as Syk modulators
|
WO2012061415A1
(en)
|
2010-11-01 |
2012-05-10 |
Portola Pharmaceuticals, Inc. |
Oxypyrimidines as syk modulators
|
PL3124483T3
(pl)
|
2010-11-10 |
2020-03-31 |
Genentech, Inc. |
Pirazolowo-aminopirymidynowe pochodne jako modulatory LRRK2
|
WO2012068549A2
(en)
|
2010-11-19 |
2012-05-24 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
CA2819118A1
(en)
|
2010-11-29 |
2012-06-07 |
Hetero Research Foundation |
A process for the preparation of pazopanib using novel intermediate
|
CN102093339B
(zh)
*
|
2010-12-09 |
2013-06-12 |
天津药物研究院 |
一类嘧啶衍生物的制备及用途
|
CN102060848B
(zh)
*
|
2010-12-09 |
2013-09-18 |
天津药物研究院 |
芳香胺取代的嘧啶衍生物的制备及用途
|
CN102093340B
(zh)
*
|
2010-12-09 |
2013-07-17 |
天津药物研究院 |
2-甲基吲唑衍生物的制备及用途
|
US8709420B2
(en)
|
2010-12-17 |
2014-04-29 |
Glaxosmithkline Intellectual Property Limited |
Pharmaceutical combination of pazopanib and topotecan to treat neuroblastoma, osteosarcoma, and rhabdomyosarcoma in a human
|
FR2968999B1
(fr)
|
2010-12-20 |
2013-01-04 |
Guerbet Sa |
Nanoemulsion de chelate pour irm
|
EP2672969A4
(de)
|
2011-02-01 |
2014-07-16 |
Glaxosmithkline Intellectual Property Ltd |
Kombination
|
EP2937349B1
(de)
|
2011-03-23 |
2016-12-28 |
Amgen Inc. |
Fusionierte tricyclische duale inhibitoren von cdk 4/6 und flt3
|
JP5886411B2
(ja)
|
2011-03-24 |
2016-03-16 |
ノビガ・リサーチ・エービーNoviga Research AB |
新規のピリミジン誘導体
|
AU2012244745A1
(en)
*
|
2011-04-19 |
2013-09-19 |
Bayer Intellectual Property Gmbh |
Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines
|
CN103501612B
(zh)
|
2011-05-04 |
2017-03-29 |
阿里亚德医药股份有限公司 |
抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
|
TWI555737B
(zh)
*
|
2011-05-24 |
2016-11-01 |
拜耳知識產權公司 |
含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
|
EP2739252A4
(de)
|
2011-08-05 |
2015-08-12 |
Forsight Vision4 Inc |
Abgabe kleiner moleküle über eine implantierbare therapeutische vorrichtung
|
WO2013025939A2
(en)
|
2011-08-16 |
2013-02-21 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
JP5976814B2
(ja)
*
|
2011-09-16 |
2016-08-24 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH |
スルホキシイミン基を含有する二置換5−フルオロピリミジン誘導体
|
FR2980364B1
(fr)
|
2011-09-26 |
2018-08-31 |
Guerbet |
Nanoemulsions et leur utilisation comme agents de contraste
|
US9278099B2
(en)
|
2011-10-31 |
2016-03-08 |
Novartis Ag |
Pazopanib formulation
|
US9359308B2
(en)
|
2011-11-23 |
2016-06-07 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
CN103159742B
(zh)
*
|
2011-12-16 |
2015-08-12 |
北京韩美药品有限公司 |
5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
CN103373989B
(zh)
*
|
2012-04-28 |
2016-04-13 |
上海医药工业研究院 |
盐酸帕唑帕尼的中间体的制备方法
|
WO2013169401A1
(en)
|
2012-05-05 |
2013-11-14 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
US9505749B2
(en)
|
2012-08-29 |
2016-11-29 |
Amgen Inc. |
Quinazolinone compounds and derivatives thereof
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
US9708293B2
(en)
|
2012-10-18 |
2017-07-18 |
Bayer Pharma Aktiengesellschaft |
N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
|
CA2888371C
(en)
|
2012-10-18 |
2021-06-08 |
Ulrich Lucking |
5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
|
TW201418243A
(zh)
|
2012-11-15 |
2014-05-16 |
Bayer Pharma AG |
含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
|
ME02880B
(de)
|
2012-11-15 |
2018-04-20 |
Bayer Pharma AG |
5-fluor-n-(pyridin-2-yl)pyridin-2-amin-derivate mit einer sulfoximingruppe
|
CN103864764A
(zh)
*
|
2012-12-11 |
2014-06-18 |
齐鲁制药有限公司 |
吲唑取代的嘧啶胺衍生物、其制备方法和用途
|
ES2669425T3
(es)
*
|
2012-12-17 |
2018-05-25 |
Sun Pharmaceutical Industries Limited |
Procedimiento para la preparación de pazopanib o sales del mismo
|
WO2014097152A1
(en)
|
2012-12-17 |
2014-06-26 |
Ranbaxy Laboratories Limited |
Process for the preparation of pazopanib or salts thereof
|
CN103910716A
(zh)
*
|
2013-01-07 |
2014-07-09 |
华东理工大学 |
2,4-二取代-环烷基[d]嘧啶类化合物及其用途
|
WO2014108837A1
(en)
|
2013-01-09 |
2014-07-17 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination
|
FR3001154B1
(fr)
|
2013-01-23 |
2015-06-26 |
Guerbet Sa |
Magneto-emulsion vectorisee
|
AU2014236455B2
(en)
|
2013-03-14 |
2018-07-12 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
CN103214467B
(zh)
*
|
2013-04-26 |
2015-09-30 |
中国人民解放军军事医学科学院微生物流行病研究所 |
5-[[4-[(2,3-二甲基-2h-吲唑-6-基)甲氨基]-2嘧啶基]氨基]-2-甲基-苯磺酰胺衍生物及其制备方法与应用
|
WO2015001021A1
(en)
|
2013-07-04 |
2015-01-08 |
Bayer Pharma Aktiengesellschaft |
Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
|
CN105659085B
(zh)
|
2013-08-28 |
2018-12-07 |
中美冠科生物技术(太仓)有限公司 |
预测受试者对多激酶抑制剂的反应的基因表达标志及其使用方法
|
WO2015056180A1
(en)
|
2013-10-15 |
2015-04-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Indoline derivatives as inhibitors of perk
|
US10730859B2
(en)
|
2013-11-05 |
2020-08-04 |
Laurus Labs Limited |
Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
|
CN103739550B
(zh)
*
|
2014-01-02 |
2016-06-01 |
中国药科大学 |
2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用
|
CN104829542B
(zh)
*
|
2014-02-10 |
2018-02-02 |
中国科学院上海药物研究所 |
苯胺嘧啶类化合物、其制备方法和医药用途
|
WO2015136463A1
(en)
|
2014-03-11 |
2015-09-17 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Chemical compounds acting as perk inhibitors
|
WO2015136028A1
(en)
|
2014-03-13 |
2015-09-17 |
Bayer Pharma Aktiengesellschaft |
5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
|
WO2015150273A1
(en)
|
2014-04-01 |
2015-10-08 |
Bayer Pharma Aktiengesellschaft |
Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
|
BR112016023554B1
(pt)
|
2014-04-11 |
2023-03-14 |
Bayer Pharma Aktiengesellschaft |
Novos compostos macrocíclicos
|
US9856263B2
(en)
|
2014-04-28 |
2018-01-02 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
EP3177289A4
(de)
|
2014-08-08 |
2018-03-21 |
Forsight Vision4, Inc. |
Stabile und lösliche formulierungen von rezeptortyrosinkinaseinhibitoren und verfahren zur herstellung davon
|
WO2016055935A1
(en)
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
US9884849B2
(en)
|
2014-10-16 |
2018-02-06 |
Bayer Pharma Aktiengesellschaft |
Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
|
EP3207037B1
(de)
|
2014-10-16 |
2019-01-23 |
Bayer Pharma Aktiengesellschaft |
Fluorierte benzofuranylpyrimidinderivate mit einer sulfongruppe
|
JP7041515B2
(ja)
|
2015-01-08 |
2022-03-24 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
骨、骨髄、及び軟骨の誘導を提供する因子及び細胞
|
US20180000771A1
(en)
|
2015-01-13 |
2018-01-04 |
Kyoto University |
Agent for preventing and/or treating amyotrophic lateral sclerosis
|
KR101705980B1
(ko)
*
|
2015-06-12 |
2017-02-13 |
중앙대학교 산학협력단 |
신규 파조파닙 유도체 및 이를 함유하는 약학조성물
|
CN105237523B
(zh)
*
|
2015-10-08 |
2018-06-01 |
深圳市博圣康生物科技有限公司 |
嘧啶衍生物及其制备方法、用途
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
EP3228630A1
(de)
|
2016-04-07 |
2017-10-11 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Kombination eines apelin-antagonisten und angiogeneseinhibitor zur behandlung von krebs
|
AU2017279029A1
(en)
|
2016-06-08 |
2018-12-20 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as ATF4 pathway inhibitors
|
WO2017212423A1
(en)
|
2016-06-08 |
2017-12-14 |
Glaxosmithkline Intellectual Property Development Limited |
Chemcical compounds
|
EP3487503A1
(de)
|
2016-07-20 |
2019-05-29 |
GlaxoSmithKline Intellectual Property Development Limited |
Isochinolinderivate als perk-inhibitoren
|
CA3045752A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
CR20190338A
(es)
|
2016-12-22 |
2019-09-09 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso
|
WO2018148533A1
(en)
|
2017-02-09 |
2018-08-16 |
Georgetown University |
Compositions and methods for treating lysosomal storage disorders
|
US11242356B2
(en)
|
2017-03-28 |
2022-02-08 |
Bayer Aktiengesellschaft |
PTEFb inhibiting macrocyclic compounds
|
PL3601253T3
(pl)
|
2017-03-28 |
2022-01-17 |
Bayer Aktiengesellschaft |
Nowe hamujące ptefb związki makrocykliczne
|
JP7108018B2
(ja)
|
2017-04-17 |
2022-07-27 |
イエール ユニバーシティ |
急性肺傷害を処置または予防する化合物、組成物および方法
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
WO2019008507A1
(en)
|
2017-07-03 |
2019-01-10 |
Glaxosmithkline Intellectual Property Development Limited |
2- (4-CHLOROPHENOXY) -N - ((1- (2- (4-CHLOROPHENOXY) ETHYNAZETIDIN-3-YL) METHYL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF ATF4 FOR THE TREATMENT OF CANCER AND D OTHER DISEASES
|
CA3068753A1
(en)
|
2017-07-03 |
2019-01-10 |
Glaxosmithkline Intellectual Property Development Limited |
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
CN107619407B
(zh)
*
|
2017-08-10 |
2019-05-24 |
山东大学 |
基于帕唑帕尼结构的hdac和vegfr双靶点抑制剂及其制备方法和应用
|
TW201922721A
(zh)
|
2017-09-07 |
2019-06-16 |
英商葛蘭素史克智慧財產發展有限公司 |
化學化合物
|
CN116003405A
(zh)
|
2017-09-08 |
2023-04-25 |
美国安进公司 |
Kras g12c的抑制剂及其使用方法
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
SG11202006470RA
(en)
|
2018-02-13 |
2020-08-28 |
Bayer Ag |
Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
WO2019053500A1
(en)
|
2018-04-17 |
2019-03-21 |
Alvogen Malta Operations (Row) Ltd |
PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE FORM CONTAINING PAZOPANIB AND PROCESS FOR PREPARING THE SAME
|
MX2020010836A
(es)
|
2018-05-04 |
2021-01-08 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso.
|
WO2019213526A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CA3099045A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
EP3802535B1
(de)
|
2018-06-01 |
2022-12-14 |
Amgen, Inc |
Kras-g12c-inhibitoren und verfahren zur verwendung davon
|
WO2019241157A1
(en)
|
2018-06-11 |
2019-12-19 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
MX2020012261A
(es)
|
2018-06-12 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
|
EP3806858A4
(de)
|
2018-06-15 |
2022-03-09 |
Handa Pharmaceuticals, Inc. |
Kinaseinhibitorsalze und zusammensetzungen davon
|
WO2020007822A1
(en)
|
2018-07-02 |
2020-01-09 |
Conservatoire National Des Arts Et Metiers (Cnam) |
Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
|
CA3105942A1
(en)
|
2018-07-09 |
2020-01-16 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
US11053226B2
(en)
|
2018-11-19 |
2021-07-06 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
BR112021010353A2
(pt)
|
2018-11-30 |
2021-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Compostos úteis em terapia hiv
|
MX2021007104A
(es)
|
2018-12-20 |
2021-08-11 |
Amgen Inc |
Inhibidores de kif18a.
|
AR117490A1
(es)
|
2018-12-20 |
2021-08-11 |
Amgen Inc |
Inhibidores de kif18a
|
JP2022513967A
(ja)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
WO2020132653A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
BR112021011894A2
(pt)
|
2018-12-21 |
2021-09-08 |
Daiichi Sankyo Company, Limited |
Composição farmacêutica
|
KR20210146288A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로사이클릴 화합물 및 이의 용도
|
WO2020180768A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
CA3140392A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
WO2021018941A1
(en)
|
2019-07-31 |
2021-02-04 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
MX2022001296A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
EP4007756A1
(de)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Kif18a-inhibitoren
|
JP2022542967A
(ja)
|
2019-08-02 |
2022-10-07 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
CN110746402B
(zh)
*
|
2019-09-21 |
2021-01-15 |
温州医科大学 |
一种2-n-芳基-4-n-芳基-5-氟嘧啶类化合物及其制备方法和应用
|
EP4048671A1
(de)
|
2019-10-24 |
2022-08-31 |
Amgen Inc. |
Pyridopyrimidinderivate als kras-sg12c- und kras-g12d-inhibitoren zur behandlung von krebs
|
CA3159561A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
MX2022005357A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
CR20220243A
(es)
|
2019-11-04 |
2022-08-04 |
Revolution Medicines Inc |
Inhibidores de ras
|
BR112022008858A2
(pt)
|
2019-11-08 |
2022-09-06 |
Revolution Medicines Inc |
Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
|
US20230192682A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
IL292315A
(en)
|
2019-11-14 |
2022-06-01 |
Amgen Inc |
Improved synthesis of a kras g12c inhibitory compound
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
BR112022010086A2
(pt)
|
2020-01-07 |
2022-09-06 |
Revolution Medicines Inc |
Dosagem do inibidor de shp2 e métodos de tratamento de câncer
|
EP4149475A1
(de)
|
2020-05-22 |
2023-03-22 |
QX Therapeutics Inc. |
Zusammensetzungen und verfahren zur behandlung von lungenverletzungen in zusammenhang mit virusinfektionen
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
WO2022040446A1
(en)
|
2020-08-19 |
2022-02-24 |
Nanocopoeia, Llc |
Amorphous pazopanib particles and pharmaceutical compositions thereof
|
AU2021344830A1
(en)
|
2020-09-03 |
2023-04-06 |
Revolution Medicines, Inc. |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
CN116457358A
(zh)
|
2020-09-15 |
2023-07-18 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
EP4267250A1
(de)
|
2020-12-22 |
2023-11-01 |
Qilu Regor Therapeutics Inc. |
Sos1-inhibitoren und verwendungen davon
|
CN118234731A
(zh)
|
2021-05-05 |
2024-06-21 |
锐新医药公司 |
Ras抑制剂
|
EP4334324A1
(de)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Kovalente ras-inhibitoren und verwendungen davon
|
IL308195A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors for cancer treatment
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
WO2023230541A1
(en)
|
2022-05-27 |
2023-11-30 |
Viiv Healthcare Company |
Piperazine derivatives useful in hiv therapy
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|